| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | NAVIGEN INC | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | U44AI095172 | A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV | 000 | 10 | NIH | 1/23/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,000,000 ) |
| | 2022 | 2022 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | U44AI095172 | A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV | 001 | 10 | NIH | 4/7/2022 | $1,000,000 |
| | 2022 | 2020 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | U44AI095172 | A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV | 000 | 8 | NIH | 3/31/2022 | $0 |
| | 2022 | 2019 | NAVIGEN INC | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | SB1AI095172 | Therapeutic D-peptide Inhibitor of HIV Entry | 000 | 7 | NIH | 11/5/2021 | $0 |
| | 2022 | 2019 | NAVIGEN INC | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | R01AI127092 | Depot formulation of a D-peptide HIV entry inhibitor | 000 | 3 | NIH | 2/28/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,000,000 ) |
| | 2021 | 2021 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | U44AI095172 | A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV | 000 | 9 | NIH | 3/30/2021 | $1,000,000 |
| | 2021 | 2019 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | R43HL147780 | Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | 000 | 1 | NIH | 7/16/2021 | $0 |
| | 2021 | 2019 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | R43DK117777 | Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | 000 | 2 | NIH | 3/19/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,000,000 ) |
| | 2020 | 2020 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | U44AI095172 | A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV | 000 | 8 | NIH | 4/24/2020 | $1,000,000 |
| | 2020 | 2020 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | U44AI095172 | A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV | 001 | 8 | NIH | 4/30/2020 | $0 |
| | 2020 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R43HL147780 | Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | 000 | 1 | NIH | 11/19/2019 | $0 |
| | 2020 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R43HL147780 | Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | 001 | 1 | NIH | 1/7/2020 | $0 |
| | 2020 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R43HL147780 | Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | 002 | 1 | NIH | 3/13/2020 | $0 |
| | 2020 | 2019 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | SB1AI095172 | Therapeutic D-peptide Inhibitor of HIV Entry | 000 | 7 | NIH | 4/16/2020 | $0 |
| | 2020 | 2018 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | R44HL127886 | ARF6 Inhibitors for Treatment of Acute Lung Injury | 000 | 3 | NIH | 12/23/2019 | $0 |
| | 2020 | 2018 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | R44AI098197 | Preclinical development of a potent D-peptide RSV inhibitor | 000 | 5 | NIH | 12/23/2019 | $0 |
| | 2020 | 2018 | NAVIGEN, INC. | 675 S ARAPEEN DR | SALT LAKE CITY | UT | 84108-1223 | SALT LAKE | USA | R43AI141129 | ARF6 Inhibitor as Adjunctive Therapy for Treatment of SA Bacteremia | 000 | 1 | NIH | 12/19/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,926,724 ) |
| | 2019 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R43HL147780 | Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza | 000 | 1 | NIH | 9/23/2019 | $268,075 |
| | 2019 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | SB1AI095172 | Therapeutic D-peptide Inhibitor of HIV Entry | 000 | 7 | NIH | 7/31/2019 | $1,000,000 |
| | 2019 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R01AI127092 | Depot formulation of a D-peptide HIV entry inhibitor | 000 | 3 | NIH | 7/29/2019 | $551,835 |
| | 2019 | 2019 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R43DK117777 | Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | 001 | 2 | NIH | 7/25/2019 | $106,814 |
| | 2019 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43DK117777 | Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | 000 | 1 | NIH | 10/25/2018 | $0 |
| | 2019 | 2017 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R43CA224710 | D-peptide inhibitors of SIRP? anti-phagocytic signaling | 000 | 1 | NIH | 1/31/2019 | $0 |
| | 2019 | 2017 | NAVIGEN, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1245 | SALT LAKE | USA | R44AI102347 | Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | 000 | 5 | NIH | 2/7/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $3,905,119 ) |
| | 2018 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | SB1AI095172 | Therapeutic D-peptide Inhibitor of HIV Entry | 000 | 6 | NIH | 8/3/2018 | $1,000,000 |
| | 2018 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43DK117777 | Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | 000 | 1 | NIH | 9/18/2018 | $216,252 |
| | 2018 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43AI141129 | ARF6 Inhibitor as Adjunctive Therapy for Treatment of SA Bacteremia | 000 | 1 | NIH | 8/3/2018 | $300,000 |
| | 2018 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R01AI127092 | Depot formulation of a D-peptide HIV entry inhibitor | 000 | 2 | NIH | 7/18/2018 | $571,590 |
| | 2018 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44HL127886 | ARF6 Inhibitors for Treatment of Acute Lung Injury | 000 | 3 | NIH | 5/24/2018 | $817,279 |
| | 2018 | 2018 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44AI098197 | Preclinical development of a potent D-peptide RSV inhibitor | 000 | 5 | NIH | 7/17/2018 | $999,998 |
| | 2018 | 2016 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43AI120414 | Highly specific anti-toxin therapies for severe bacterial gut infections | 000 | 2 | NIH | 3/13/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $4,939,717 ) |
| | 2017 | 2017 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | SB1AI095172 | Therapeutic D-peptide Inhibitor of HIV Entry | 000 | 5 | NIH | 9/18/2017 | $1,000,000 |
| | 2017 | 2017 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44AI102347 | Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | 000 | 5 | NIH | 3/29/2017 | $894,941 |
| | 2017 | 2017 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44AI098197 | Preclinical development of a potent D-peptide RSV inhibitor | 000 | 4 | NIH | 7/28/2017 | $999,998 |
| | 2017 | 2017 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R01AI127092 | Depot formulation of a D-peptide HIV entry inhibitor | 000 | 1 | NIH | 8/15/2017 | $826,272 |
| | 2017 | 2017 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44HL127886 | ARF6 Inhibitors for Treatment of Acute Lung Injury | 000 | 2 | NIH | 4/25/2017 | $889,461 |
| | 2017 | 2017 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43CA224710 | D-peptide inhibitors of SIRP? anti-phagocytic signaling | 000 | 1 | NIH | 9/19/2017 | $299,945 |
| | 2017 | 2016 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R56AI127092 | Depot formulation of a D-peptide HIV entry inhibitor | 000 | 1 | NIH | 5/3/2017 | $29,100 |
| | 2017 | 2015 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44AR063509 | Blocking a novel cytokine signaling pathway for the treatment of rheumatoid arthr | 000 | 3 | NIH | 1/10/2017 | $0 |
| | 2017 | 2015 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R44AI095172 | Therapeutic D-peptide Inhibitor of HIV Entry | 000 | 4 | NIH | 4/3/2017 | $0 |
| | 2017 | 2015 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43CA192545 | Arf6 inhibitors for the treatment of uveal melanoma | 000 | 1 | NIH | 5/1/2017 | $0 |
| | 2017 | 2015 | NAVIGEN PHARMACEUTICALS, INC. | 383 COLOROW DR | SALT LAKE CITY | UT | 84108-1201 | SALT LAKE | USA | R43DA039601 | Developing a Peripherally-Acting Peptidic Galanin Analog for Treatment of Postoperative Pain | 000 | 1 | NIH | 4/11/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $2,785,472 ) (Continued on the next page) |
|
